Skip to main content
SinoMab BioScience Limited logo

SinoMab BioScience Limited — Investor Relations & Filings

Ticker · 3681 ISIN · HK0000544194 LEI · 9845009B6CEEC4694006 HKEX Manufacturing
Filings indexed 319 across all filing types
Latest filing 2023-09-11 Regulatory Filings
Country HK Hong Kong
Listing HKEX 3681

About SinoMab BioScience Limited

http://www.sinomab.com

SinoMab BioScience Limited is a clinical-stage biopharmaceutical company specializing in the research, development, and commercialization of therapeutic antibodies. The company focuses on developing novel, highly efficacious drugs, including "first-in-class" and "best-in-class" candidates, primarily for the treatment of immunological and life-threatening diseases, such as rheumatoid arthritis. SinoMab maintains full-spectrum drug development capabilities, covering antibody re-engineering, bioprocessing, and manufacturing, aimed at addressing significant unmet medical needs globally.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT IND APPROVAL FOR SM17 BY NMPA
Regulatory Filings
2023-09-11 English
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
Regulatory Filings
2023-09-06 English
CHANGE OF NON-EXECUTIVE DIRECTORS
Regulatory Filings
2023-09-06 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2023
Regulatory Filings
2023-09-05 English
VOLUNTARY ANNOUNCEMENT BLA ACCEPTED BY THE NMPA FOR SM03 (SUCIRASLIMAB) IN THE TREATMENT OF RHEUMATOID ARTHRITIS
Regulatory Filings
2023-09-05 English
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2023
Regulatory Filings
2023-08-21 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.